MetLife Investment Management LLC Sells 1,443 Shares of Revolution Medicines, Inc. $RVMD

by · The Markets Daily

MetLife Investment Management LLC lessened its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,886 shares of the company’s stock after selling 1,443 shares during the period. MetLife Investment Management LLC’s holdings in Revolution Medicines were worth $3,497,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in shares of Revolution Medicines by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 12,792 shares of the company’s stock valued at $452,000 after buying an additional 259 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Revolution Medicines by 11.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,221 shares of the company’s stock valued at $232,000 after buying an additional 615 shares in the last quarter. GF Fund Management CO. LTD. boosted its holdings in shares of Revolution Medicines by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 4,307 shares of the company’s stock valued at $152,000 after buying an additional 775 shares in the last quarter. Xponance Inc. boosted its holdings in shares of Revolution Medicines by 6.7% during the 1st quarter. Xponance Inc. now owns 12,937 shares of the company’s stock valued at $457,000 after buying an additional 810 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in shares of Revolution Medicines by 17.1% during the 4th quarter. Mackenzie Financial Corp now owns 6,055 shares of the company’s stock valued at $265,000 after buying an additional 885 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $37.97 on Friday. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The business has a 50-day simple moving average of $37.26 and a two-hundred day simple moving average of $38.18. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79. The firm has a market cap of $7.10 billion, a price-to-earnings ratio of -8.44 and a beta of 1.16.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.37). During the same period last year, the firm earned ($0.81) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

RVMD has been the topic of a number of research reports. Wells Fargo & Company initiated coverage on shares of Revolution Medicines in a report on Friday, August 15th. They set an “overweight” rating and a $67.00 target price on the stock. Oppenheimer lifted their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Guggenheim reaffirmed a “buy” rating and issued a $80.00 price target on shares of Revolution Medicines in a research report on Wednesday, June 25th. The Goldman Sachs Group started coverage on Revolution Medicines in a research report on Tuesday, July 15th. They issued a “buy” rating and a $65.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $73.00 price target (up previously from $67.00) on shares of Revolution Medicines in a research report on Tuesday, June 24th. Thirteen research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $69.92.

Check Out Our Latest Stock Analysis on Revolution Medicines

Revolution Medicines Profile

(Free Report)

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

See Also

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).